Singapore, May 26 -- Taiwan headquarteredBora Biologics, a leading contract development and manufacturing organization (CDMO) specialising in biologics manufacturing, has announced a major expansion of its US FDA-registered commercial manufacturing facility in San Diego, US.
This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a premier biologics CDMO.
The expansion adds 8,075 square feet of state-of-the-art GMP manufacturing space to the San Diego biologics manufacturing facility, comprising a cutting-edge upstream mammalian cell culture hall, harvest suite with two inoculatio...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.